We are live on ! Find out more
EYEGW

Eyegate Pharmaceuticals, Inc. Warrants
EYEGW

Delisted

EYEGW was delisted on the 5th of August, 2020.

Back to rankings

3 hedge funds and large institutions have $13K invested in Eyegate Pharmaceuticals, Inc. Warrants in 2018 Q1 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% less funds holding

Funds holding: 4 → 3 (-1)

48% less capital invested

Capital invested by funds: $25K → $13K (-$12K)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
3
Holders Change
-1
Holders Change %
-25%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2K
2
VF
Virtu Financial
New York
-$2K
Name Holding Trade Value Shares
Change 		Change in
Stake
AIC
1
AWM Investment Company
New York
$12K – – –
CH
2
CVI Holdings
Delaware
$1K +$1.57K +12,900 New
Susquehanna International Group
3
Susquehanna International Group
Pennsylvania
– -$2K -12,900 Closed
VF
4
Virtu Financial
New York
– -$2K -12,391 Closed

EYEGW Hedge Fund Activity: Q1 2018 in Review

3 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) for Q1 2018, worth a combined $13K — down 48% from $25K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of EYEGW and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 0 added.

The largest seller was Susquehanna International Group, exiting entirely with an estimated $2K sold.

  • 3 institutional investors held Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) as of Q1 2018, down from 4 in Q4 2017.
  • Funds reported $13K of Eyegate Pharmaceuticals, Inc. Warrants stock for Q1 2018, down 48% quarter-over-quarter.
  • 1 fund opened new Eyegate Pharmaceuticals, Inc. Warrants positions in Q1 2018 and 2 closed out, a net change of -1 holder.
  • The largest Eyegate Pharmaceuticals, Inc. Warrants seller in Q1 2018 was Susquehanna International Group, an estimated $2K sold.

Based on aggregated 13F filings for Q1 2018.